Comparative Pharmacology
Head-to-head clinical analysis: ERGOTAMINE TARTRATE AND CAFFEINE versus WIGRETTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERGOTAMINE TARTRATE AND CAFFEINE versus WIGRETTES.
ERGOTAMINE TARTRATE AND CAFFEINE vs WIGRETTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ergotamine is a partial agonist/antagonist at serotonin (5-HT), dopamine, and alpha-adrenergic receptors, causing vasoconstriction of cranial blood vessels. Caffeine enhances ergotamine absorption and has additive vasoconstrictive effects.
Nicotine replacement therapy: binds to nicotinic acetylcholine receptors in the brain, releasing dopamine and providing nicotine to reduce withdrawal symptoms and cravings.
Oral: 2 mg ergotamine tartrate and 200 mg caffeine at onset of migraine, then 1 mg ergotamine tartrate and 100 mg caffeine every 30 minutes as needed; maximum 6 mg ergotamine tartrate and 600 mg caffeine per day or 10 mg ergotamine tartrate and 1000 mg caffeine per week. Rectal: 2 mg ergotamine tartrate and 200 mg caffeine as a single suppository at onset; repeat once after 1 hour if needed; maximum 4 mg ergotamine tartrate and 400 mg caffeine per day or 8 mg ergotamine tartrate and 800 mg caffeine per week.
1 mg sublingually as needed for smoking cessation, up to 4 times daily. Maximum daily dose: 4 mg.
None Documented
None Documented
Ergotamine has a terminal elimination half-life of approximately 2 hours (range 1.5–2.5 hours) for the alpha phase, but a longer terminal half-life of 12–24 hours due to slow tissue release; this contributes to its prolonged duration of action and risk of accumulation with frequent dosing.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-30 hours in moderate renal impairment.
Ergotamine is primarily excreted in bile and feces as metabolites, with approximately 90% of a dose eliminated via the biliary-fecal route and less than 4% excreted unchanged in urine. Caffeine is extensively metabolized in the liver and its metabolites are excreted renally, with only about 1% excreted unchanged.
Renal excretion of unchanged drug accounts for 50-60% of the dose; biliary/fecal elimination accounts for 20-30%; remainder metabolized.
Category D/X
Category C
Ergot Alkaloid
Ergot Alkaloid